{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-009202","form_type":"8-K","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.326219+00:00","generated_at":"2026-06-17T14:08:08.313926+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ProPhase Labs reports record FY2022 revenue of $122.6M (+55% YoY), net income $18.5M","bullets":["Revenue $122.6M vs $79.0M in 2021 (+55%); net income $18.5M ($1.17 diluted) vs $6.3M ($0.41).","Adjusted EBITDA $38.6M vs $18.1M; includes $5.9M bad debt write-off from HRSA policy change.","Cash & equivalents $9.1M, working capital $44.8M; paid $9.3M dividends, repurchased 1.3M shares for $11.3M.","Subsequent to year-end: acquired exclusive worldwide rights to BE-Smart esophageal cancer test; Board authorized new $6M stock buyback.","Management expects COVID-19 testing to slow but sees growth in Pharmaloz, Nebula Genomics, and BE-Smart test."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-009202","json":"https://secwatch.observer/filing/0001493152-23-009202.json","markdown":"https://secwatch.observer/filing/0001493152-23-009202.md","text":"https://secwatch.observer/filing/0001493152-23-009202.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000149315223009202/0001493152-23-009202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000149315223009202/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T14:08:08.313926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03f518bf64c915081539c4f09f33ae4a7e6bb545","claim":"ProPhase Labs, Inc. reported the year ended December 31, 2022 results: revenue $122.6 million, net income $18.5 million, EPS $1.17 per diluted share.","evidence_excerpt":"Financial highlights for the full year ended December 31, 2022, include the following: ● Net revenue of $122.6 million for the year ended December 31, 2022, as compared to $79.0 million for the year ended December 31, 2021, an increase of approximately 55%. ● Net Income of $18.5 million, or $1.17 per diluted share, for the year ended December 31, 2022, as compared to net income of $6.3 million, or $0.41 per share, for the year ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000149315223009202/0001493152-23-009202-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$122.6 million"},{"label":"Net income","value":"$18.5 million"},{"label":"EPS","value":"$1.17 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}